ArticleInternational journal of clinical and experimental pathology2020
Toll-like receptor 3 (TLR3) functions as a pivotal target in latent membrane protein 1 (LMP1)-mediated nasopharyngeal carcinoma cell proliferation.
Article in International journal of clinical and experimental pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 7 citations in OpenAlex.
- Creating an interactive database for nasopharyngeal carcinoma management: applying machine learning to evaluate metastasis and survival.Frontiers in oncology · 2024Article
- Review
- Epstein-Barr virus variation in people living with human immunodeficiency virus in southeastern China.Virology journal · 2023Article
- Rintatolimod: a potential treatment in patients with pancreatic cancer expressing Toll-like receptor 3.American journal of cancer research · 2023Article
- High-Risk Human Papillomavirus and Epstein-Barr Virus Coinfection: A Potential Role in Head and Neck Carcinogenesis.Biology · 2021Review
- Anti-viral and pro-inflammatory functions of Toll-like receptors during gamma-herpesvirus infections.Virology journal · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) activation of NF-κB is pivotal for EBV-infected B lymphocyte survival. Herein, we found that LMP1 markedly rescued the suppressed the proliferation of several nasopharyngeal carcinoma (NPC) cell lines caused by a Toll-like receptor 3 (TLR3) ligand poly (I:C). We profiled the expression alterations of TLR3 and LMP1 within these NPC cell lines in response to poly (I:C) treatment, and found a high correlation between them ws found, suggesting potential involvement of TLR3 in LMP1 signaling. Then, cells deficient in TLR3 were used to assess its role in poly (I:C)-induced inhibition of cell proliferation and LMP1-mediated NF-κB activation. NF-κB p65 activation and the consequent pro-inflammatory responses were unresponsive to poly (I:C) stimulation after TLR3 knockdown (KD), and NOS2 and MMP9 were substantially suppressed in CNE1-745, but nearly normal in LMP1-overexpressed CNE1-LMP1-745 cells. This suggests an alternative pathway that LMP1 may depend on, in terms of NOS2 and MMP9 regulation, whereas an unusual TLR3-dependent expression of c-Myc was identified. Consistently, poly (I:C)-induced retarded growth was reversed by TLR3 silencing, which was especially enhanced in LMP1-overexpressed cells. TLR3 is essential for poly (I:C)-incited NPC cell death, and occupies a critical role in LMP1-mediated NF-κB activation. Our findings provide new insight into the mechanism underlying LMP1-involved EBV-associated pathogenesis of refractory NPC, thereby potentially improving treatment outcome.
Indexed as
Identifiers
32211095PMC7061799W3015618935What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.